汇聚群英智慧，闪亮你我星光
Together, Spark Biomedicine!
各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。
本月热点
TOPICS
Summit/Akeso’s PD1 X VEGF bispecific antibody Ivonescimab showed PFS benefit over Keytruda in 1L NSCLC phase 3 study;
Biotheus announced phase 2 data of their PD-L1 X VEGF bispecific antibody;
Eli Lilly launched 750-patient phase 1 study for their pan-KRAS inhibitor;
Amgen’s PRMT5 inhibitor AMG193 showed preliminary clinical activity in MTAP-deleted solid tumors;
Astellas provided phase 1 updates on KRAS G12D degrader ASP3082;
BMS launched phase 3 study of anti-PD1 + anti-LAG3 combination therapy in 1L NSCLC;
AstraZeneca / Daiichi's TROP2-directed ADC failed to improve overall survival in phase 3 trials of breast cancer and NSCLC;
Boehringer Ingelheim's nerandomilast met the primary end point in the pivotal phase 3 FIBRONEER-IPF trial;
UCB & Biogen announced positive topline phase 3 results of Dapirolizumab Pegol in SLE, ready to initiate a second phase 3 study;
Candid Therapeutics debuts with $370M in seed funding and a 3-way merger by acquiring Vignette Bio and TRC 2004;
Amgen announced topline phase 3 data for anti-OX40 in atopic dermatitis;
Organon pays up to $1.2B to acquire Dermavant;
Amgen provided phase 3 updates on their anti-CD19 Uplizna for myasthenia gravis;
Novo Nordisk’s CB1 inverse agonist showed modest results in weight loss, raising concerns of psychiatric side effects.
活动详情
主题：Monthly biotech news discussion - September 2024 in review
时间：2024年09月28日 Sat 9:00 PM（EST）/ 2024年09月29日 周日 早上9:00 AM（北京时间）
地点：zoom meeting（扫描二维码获得zoom注册链接或点击文末“阅读原文”）
嘉宾：
Jimmy Wang (王俊), Assistant Professor @ New York University
(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)
Ethan Xu (徐亦迅),VP of Bioinformatics @ Aspen Neuroscience
(http://linkedin.com/in/ethan-yixun-xu-2b915a4)
Yanran He (何嫣然), Investment Director @ Sinopharm-CICC
(https://www.linkedin.cn/injobs/in/yanranhe)
Lihua Yu (于利华), Chief Data Officer @ Fogpharma
(https://www.linkedin.com/in/lihua-yu-5b3337)
Leon 'Jun' TANG (唐钧), Founding Partner @ InScienceWeTrust BioAdvisory
(https://www.linkedin.com/in/leontangnyc/)
Charlene Liao (廖晓伶), CEO @ Immune-Onc Therapeutics, Inc. (http://linkedin.com/in/charlene-liao-a1872a55)
Haoran Wang(王浩然), CEO @ Weihai Neoland Biosciences Co.,Ltd.
(https://www.linkedin.com/in/hao-ran-wang-228648b)
Yongjiang Hei (黑永疆), Co-CEO @ Biocity Biopharma
( http://linkedin.com/in/yonghei)
Wenjun Wu (Armstrong,吴文君), Director @ HanKang Venture
(https://www.linkedin.com/in/文君-吴-14787b95/)
本期活动组织：Ethan Xu & Jimmy Wang
本月热点总结：Armstrong和monthly news嘉宾
活动直播伙伴
About us
BioSpark
BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。
BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.
成为BioSpark会员：BioSpark期待您的加入--会员推荐与申请
Follow us on Twitter:
https://twitter.com/BioSpark_Group
Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group
BioSpark events Calendar:
https://tinyurl.com/tcwy44t6
Email us: info@BioSpark.org
合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group
赞 助 机 构
战 略 合 作
BioSpark Group致力于建立华人在生物医领域的生态系统和互助网络，立足于波士顿，我们在硅谷和中国与LEAP Initiative、Dahshu和医药笔记达成战略合作。
更多精彩，请关注BioSpark公众号
